Patient-reported outcomes to assess the efficacy of extended-release guaifenesin for the treatment of acute respiratory tract infection symptoms

Table 2 Summary of DCPD between-treatment comparisons (mITT population)

	Study Day
Questions	2	3	4	5	6	7	8
1. Over the last 24 hours, how often did you bring up phlegm?
2. Over the last 24 hours, how often did your phlegm make it difficult for you to breathe?				p < 0.10
3. Over the last 24 hours, how often did you feel uncomfortable about bothering other people while bringing up phlegm?
4. Over the last 24 hours, how annoyed were you by your phlegm?
5. Over the last 24 hours, how often did your phlegm interfere with your ability to speak?			p < 0.05
6. Over the last 24 hours, how often did your phlegm prevent you from going to public places?
7. Over the last 24 hours, how often did you have to interrupt your usual activities to get rid of your phlegm?
8. Over the last 24 hours, how thick was your phlegm?			p < 0.05
9. Over the last 24 hours, how difficult was it for you to bring up phlegm?				p < 0.10
10. How much did you cough when you woke up in the morning?		p < 0.10	p < 0.05	p < 0.05		p < 0.10
11. How often did you cough during the day today?			p < 0.05			p < 0.05	p < 0.10

DCPD: Daily Cough and Phlegm Diary; mITT: modified intent-to-treat. p < 0.05: statistically significant difference between treatment groups; p < 0.10: viewed as a trend towards a significant difference between treatment groups. Note: p-values are from an ordinal logistic regression model with predictors: treatment group, center, and baseline.

ISSN: 1465-993X